Teacher Retirement System of Texas Makes New $1.23 Million Investment in Charles River Laboratories International, Inc. (NYSE:CRL)

Teacher Retirement System of Texas purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 8,180 shares of the medical research company's stock, valued at approximately $1,231,000.

Other large investors have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Charles River Laboratories International by 15.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,118 shares of the medical research company's stock valued at $952,000 after purchasing an additional 817 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in shares of Charles River Laboratories International by 13.1% in the 1st quarter. Janney Montgomery Scott LLC now owns 44,500 shares of the medical research company's stock valued at $6,698,000 after purchasing an additional 5,148 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Charles River Laboratories International by 61.6% in the 1st quarter. GAMMA Investing LLC now owns 1,398 shares of the medical research company's stock valued at $210,000 after purchasing an additional 533 shares in the last quarter. Blue Trust Inc. increased its holdings in Charles River Laboratories International by 60.1% during the 1st quarter. Blue Trust Inc. now owns 2,407 shares of the medical research company's stock valued at $362,000 after acquiring an additional 904 shares in the last quarter. Finally, State of Alaska Department of Revenue increased its holdings in Charles River Laboratories International by 1.0% during the 1st quarter. State of Alaska Department of Revenue now owns 15,914 shares of the medical research company's stock valued at $2,395,000 after acquiring an additional 150 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Trading Down 2.4%

Charles River Laboratories International stock traded down $3.88 during trading on Friday, reaching $159.78. The company had a trading volume of 518,978 shares, compared to its average volume of 1,034,082. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15. The stock's 50 day moving average price is $144.87 and its two-hundred day moving average price is $151.59. The firm has a market capitalization of $7.85 billion, a price-to-earnings ratio of -245.81, a PEG ratio of 5.40 and a beta of 1.49. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The firm had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. During the same period in the previous year, the firm earned $2.27 earnings per share. Charles River Laboratories International's revenue was down 2.7% compared to the same quarter last year. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president directly owned 19,513 shares in the company, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.30% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CRL. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and dropped their target price for the company from $188.00 to $182.00 in a report on Friday, May 23rd. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and dropped their target price for the company from $190.00 to $170.00 in a report on Friday, March 21st. Citigroup upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and raised their target price for the company from $150.00 to $200.00 in a report on Wednesday. Barclays raised their target price on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a report on Thursday, May 8th. Finally, TD Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price for the company in a report on Wednesday, May 14th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International currently has an average rating of "Hold" and a consensus price target of $174.54.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).